| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Julie McElrath | Q22006776 |
| P2860 | cites work | Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection | Q24564779 |
| Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome | Q24648628 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Coping with viral diversity in HIV vaccine design | Q33283060 | ||
| Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys | Q33712291 | ||
| Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys | Q33712578 | ||
| Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution | Q34092644 | ||
| Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. | Q34335632 | ||
| Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection | Q35020830 | ||
| Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques | Q35101333 | ||
| Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. | Q35830147 | ||
| Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial | Q36618096 | ||
| Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control | Q37054526 | ||
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
| The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection | Q37273195 | ||
| HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis | Q37413781 | ||
| Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination | Q43125298 | ||
| Evolution of innate and adaptive effector cell functions during acute HIV-1 infection | Q43425543 | ||
| Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection | Q44674538 | ||
| Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity | Q45729365 | ||
| Preservation of T Cell Proliferation Restricted by Protective HLA Alleles Is Critical for Immune Control of HIV-1 Infection | Q56600656 | ||
| CD8+ T-cell responses to different HIV proteins have discordant associations with viral load | Q57259602 | ||
| Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates | Q58758928 | ||
| Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand | Q81488462 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | S323-6 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection | |
| P478 | volume | 202 Suppl 2 |
| Q36807838 | Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes |
| Q37610683 | Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees |
| Q42225249 | DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency |
| Q30410411 | Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications |
| Q34680240 | Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections |
| Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
| Q36011269 | New paradigms for HIV/AIDS vaccine development |
| Q44665243 | Protecting the initial site of viral entry: an alternative HIV vaccine target |
| Q38018721 | Slow infection control by vaccination: paratuberculosis. |
| Q36060423 | The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope |
| Q35357663 | Treatment as prevention: preparing the way |
Search more.